English Global
Panacea Biotec's is one of the few companies that provide value through the entire chain from drug discovery to sales and marketing, from contract research to contract manufacturing, for pharmaceuticals and vaccines.
Innovation has been a great passion and priority for Panacea Biotec. Beginning with an initial focus in 1995, Panacea Biotec has come a long way to establish a cohesive network of highly sophisticated ultra modern R&D centers. A team of over 90 professional and highly talented researchers are committed to pursue the constant quest for innovation and therapeutic advancements
The core area of research & development includes Vaccine Development, Novel Drug Delivery projects, Generics with high barriers to entry and Drug Discovery (small molecules). The company’s R&D centers are recognized by the Government’s Ministry of Science and technology. For carrying out pre-clinical research, the company has an animal house and facilities for undertaking in-vitro and in-vivo microbiology, pharmacology, safety, efficacy and toxicology studies. Invigorative Research & Development requires investment in time and money.
Research & Development is the core strength of Panacea Biotec.
SAMPANN Drug Delivery R&D Centre, Lalru, Punjab
Sampann R&D centre focuses on pharmaceutical research using different innovative technologies like hydro gel based topical drug delivery system of peptides and herbal drugs, solid-solid dispersion for highly variable drugs, self-emulsifying drug delivery system (SEDDS) and controlled release drug delivery systems in different therapeutic areas. The year's successful commercialization includes Aceclofenac Controlled Release tablets and Teneligliptin tablets. Sampann is in advanced stage of development of new products including immunosuppressant molecules Sirolimus, Everolimus 0.25/0.50 mg.
Vaccine Research and Development of Sampann Drug Delivery has an excellent portfolio of innovative pediatric vaccines which protect children against dreadful diseases. These include diseases such as Diphtheria, Tetanus, Pertussis, Hepatitis B, Haemophilus influenza type b and Polio. Further to broaden the existence of Panacea Biotec in the market, the Sampann Vaccine R&D is developing the new generation vaccine formulations like pneumococcal conjugate vaccine and recombinant chimeric dengue tetravalent vaccine.
Sampann has strong focus on all areas of generic research as a short to medium term strategy and advanced drug delivery research as long term strategy with first time in world differentiated formulations. Generic and Advanced drug development encompasses both, small and large molecules.
The focus on development of value added drug delivery products that would address unmet medical need; enhance patient convenience and compliance; increase the safety profile by decreasing the side effects; augment the intellectual capital of the organization and contribute towards the organizational business goals.
Capabilities:
The central focus areas are in the fields of Oncology, Organ Transplantation, CNS, Hormonal products and developing New Drug Delivery Systems (NDDS) technologies amongst others. Its capabilities include delivery conceptualization to pharmaco-kinetic (PK) proof of concept in areas of nano-particles, liposomes, micro-particles, gastro retention and oral films.
The R&D Centre has successfully completed development of 5 key projects enabling the Company to file the ANDAs with USFDA.
Laksh: Drug Discovery Centre
The Company’s also has state – of – the art Research Center for development of New Chemical Entities.This R&D Centre has capabilities to carry out work on different aspects of drug discovery which include medical chemistry, in vitro and in vivo biology, analytical & bio-analytical research, pharmacokinetics and drug metabolism studies. It focusses on development of new chemical entities (NCEs, small molecules), API research and vaccine research.
OneStream Research Centre, New Delhi
The quality, breadth and magnitude of Biopharmaceutical Research & Development Center contributions are unrivalled . Situated in New Delhi, the Center is dedicated to carry out extensive research in vaccines and biologicals using genetic engineering, molecular biology, genomics tools, animal cell culture, fermentation, purification, formulation, serology and analytical testing techniques. The Center recognized by the Department of Scientific and Industrial Research (DSIR) of the Govt. of India has about 12 scientists working with objectives to:
OneStream Research Centre is dedicated to carry out research and development on novel and efficacious vaccines and biologicals against various epidemic/endemic diseases for global market. It focuses on providing cost effective products and process development complying with all regulatory requirements. The centre is spread over 26,000 Sq. ft. area and is dedicated to carry out extensive research in Vaccines and Biologicals using advanced genetic engineering, molecular biology, genomics tools, animal cell culture, fermentation, purification, serological and analytical techniques.
The Centre is engaged in research of new generation vaccines. It has already developed 11-valent pneumococcal conjugate vaccine (Nucovac) and is in phase-III clinical trials for tetravalent dengue vaccine. The centre has a well-established BSL-3 level containment facility to handle pathogenic viruses like H1N1, Seasonal flu and Varicella.
We have collaborated with CEPI and THSTI on 21-Feb-2022 for development of a betacoronavirus vaccine that can provide broad protection against SARS-COV-2 and other coronaviruses in support of mission to develop globally accessible vaccines with the potential to prevent the next pandemic.
Pharmaceutical Drug Product Facility at Baddi
The Company’s state-of-the-art facility at Baddi, Himachal Pradesh became operational in year 2006. The facility is equipped for bi-layer tablets, mini-tablets, complex sustained release coatings and delayed release coatings.
The Company’s cytotoxic (Anti-Cancer) facility has two lines dedicated for liquid & lyophilized vials as well as pilot scale up batches. Oncology facility is equipped for manufacturing conventional and technology based injections e.g. nano-particle and liposomal lyophilized products.
The Company's manufacturing expertise lies in solid, semi-solid, soft gelatin & liquid oral dosage forms, complex anti-cancer injectables and vaccines such as:
The pharmaceutical manufacturing facilities have approved by Indian-NRA (National Regulatory Authority) and various international regulatory authorities including US-FDA, Brazil ANVISA, Germany’s BfArM, Australia-TGA, South Africa – MCC, and follow WHO-cGMP standards.
Vaccines Drug Product Facility at Baddi
The Company's state-of-the-art facility in Baddi, Himachal Pradesh sprawls over in a complex of 23 acres of land. The facility which started its operations in year 2008 is comprised of two blocks. The three-storey production block is spread over approx. 2,800 M² construction area at each floor. The warehouse cum cold storage block measures approx. 3x2500 M².
The facility has two independent formulation suites and three filling lines for manufacturing of bacterial, viral and recombinant Vaccines including live attenuated vaccines in pre-filled syringe (PFS) and vials. The facility has large lyophilization capacity for lyophilized vaccines. The total filling capacity of this facility is approx. 600 million doses per annum in PFS, single and multi-dose vial presentations. This facility is approved by Indian NRA and is also pre-qualified by WHO for the pentavalent vaccine Easyfive-TT and bOPV.
Quality control laboratories of the facility are equipped with array of latest sophisticated analytical equipment for testing of vaccines and input materials to assure quality of the product at each stage of manufacturing.
Vaccines Drug Substance Facility at Lalru, Punjab
The Company has drug substance manufacturing facilities with dedicated blocks for manufacture of recombinant antigen, bacterial, viral polysaccharides and conjugates.
Recombinant Hepatitis B surface antigen, Haemophilus influenzae type B conjugate, Diphtheria, and Tetanus Toxoids and whole cell Pertussis drug substances are manufactured at this facility.
Panacea Biotec is, 4th Largest Vaccine Maker in India.
The Company markets its products in over 30 countries including but not limited to markets such as US, Germany, Russian Federation, Turkey, Syria, Serbia, Vietnam, Philippines, Sri Lanka, Brazil and Chile. The Company has consolidated its International Pharmaceutical Business by reducing its dependence on tender business and increasing its focus on developing, registering and marketing product portfolios catering to Chronic Therapies in private market.